Tevimbra (tislelizumab-jsgr) FDA approved to treat HER2-negative, PD-L1 expressing (CPS ≥1) EGJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic disease [150]. Here, ERBB2 is linked to metastatic neoplasm.